Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has been acclaimed as a revolution in cancer treatment following the impressive results in hematologic malignancies. Unfortunately, in patients with solid tumors, objectives responses to CAR T cells are still anecdotal, and important issues are driven by on-target but off-tumor activity of CAR T cells and by the extremely complex biology of solid tumors. Here, we will review the recent attempts to challenge the therapeutic impediments to CAR T-cell therapy in solid tumors. We will focus on the most promising strategies of antigen targeting to improve tumor specificity and address the tumor heterogeneity, efforts to circumvent the physical barriers of the tumor architecture such as subverted tumor vasculature, impediments of CAR T-cell trafficking and immune suppressive microenvironment.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-1835
Entities
People
- Barbara Savoldo
- Elisa Landoni
- Gianpietro Dotti
- Giovanni Fucà
- Loic Reppel
Organizations
- Alex's Lemonade Stand Foundation
- National Institutes of Health
- United States Department of Defense
- University of North Carolina